SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer—A multicenter, randomized phase III trial.

Christoph Rochlitz, Ralph C. Winterhalder, Martin Bigler et al.|Journal of Clinical Oncology|2014

Cited by 14